Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/35489
Title: Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases
Authors: Kevin Williams
Elizabeth Bilsland
Andrew Sparkes
Wayne Aubrey
Michael Young
Larisa N. Soldatova
Kurt De Grave
Jan Ramon
Michaela De Clare
Worachart Sirawaraporn
Stephen G. Oliver
Ross D. King
Aberystwyth University
University of Cambridge
Universidade Estadual de Campinas
Brunel University London
KU Leuven
Mahidol University
University of Manchester
Keywords: Biochemistry, Genetics and Molecular Biology;Chemical Engineering;Engineering;Materials Science
Issue Date: 6-Mar-2015
Citation: Journal of the Royal Society Interface. Vol.12, No.104 (2015)
Abstract: © 2015 The Author(s) Published by the Royal Society. All rights reserved. There is an urgent need to make drug discovery cheaper and faster. This will enable the development of treatments for diseases currently neglected for economic reasons, such as tropical and orphan diseases, and generally increase the supply of new drugs. Here, we report the Robot Scientist 'Eve' designed to make drug discovery more economical. A Robot Scientist is a laboratory automation system that uses artificial intelligence (AI) techniques to discover scientific knowledge through cycles of experimentation. Eve integrates and automates library-screening, hit-confirmation, and lead generation through cycles of quantitative structure activity relationship learning and testing. Using econometric modelling we demonstrate that the use of AI to select compounds economically outperforms standard drug screening. For further efficiency Eve uses a standardized form of assay to compute Boolean functions of compound properties. These assays can be quickly and cheaply engineered using synthetic biology, enabling more targets to be assayed for a given budget. Eve has repositioned several drugs against specific targets in parasites that cause tropical diseases. One validated discovery is that the anti-cancer compound TNP-470 is a potent inhibitor of dihydrofolate reductase from the malaria-causing parasite Plasmodium vivax.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84923260810&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/35489
ISSN: 17425662
17425689
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.